BETHANY HELM: Open Payments
NPI 1235605999 · TAMUNING, GU. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$927 in 30 payments from 9 companies in 2025. Trend: 2023 $1,497 · 2024 $785 · 2025 $927
Food & beverage: $927
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $221 |
| Alkermes, Inc. | 4 | $180 |
| Neurocrine BioSciences, Inc. | 3 | $167 |
| Otsuka America Pharmaceutical, Inc. | 7 | $144 |
| Lundbeck LLC | 4 | $93 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $59 |
| E.R. Squibb & Sons, L.L.C. | 1 | $25 |
| Indivior Inc. | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
Products named: REXULTI, AUSTEDO XR, INGREZZA, ARISTADA, CAPLYTA, ABILIFY ASIMTUFII, UZEDY, COBENFY.
Industry payments across GU — which companies pay providers there.
